H1 2024 saw a strong performance from Basilea’s anti-fungal Cresemba and based on the H1 performance the company has increased guidance for FY 2024. Cresemba is maturing in the US and European markets, however, the CHMP has recommended approval for thepaediatric population, which will extend exclusivity until Q4 2027.